Jules Bordet Institute clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   Neo-CheckRay · Neo-adjuvant Chemotherapy Combined With…Neo-CheckRay · Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

   Primary completion date changed from estimate of May 30, 2025 to Nov 30, 2024

   Jules Bordet Institute·Phase 2· NCT03875573· Registry history of NCT03875573 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

2. Minor

   SYNERGY · Paclitaxel + Carboplatin + Durvalumab With or Without…SYNERGY · Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

   Primary completion date changed from estimate of Mar 2025 to May 21, 2021

   Also in this update: Study completion pushed from Dec 2025 to Dec 2028

   Jules Bordet Institute·Phase 1/2· NCT03616886· Registry history of NCT03616886 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

3. Minor

   BREASTIFLU-1 · ICG-fluorescence Imaging for Intraoperative…BREASTIFLU-1 · ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study

   Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

   Jules Bordet Institute·Not applicable· NCT06227338· Registry history of NCT06227338 on ClinicalTrials.gov (opens the registry)

   Changed Oct 4, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.